Bioxytran, Inc (BIXT) Stock Price & Analysis

Bioxytran, Inc (BIXT) fell 4.25% to USD 0.02 as of September 8, 2026 at 14:08 UTC, according to Nexqual real-time market data.

BIXT last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 29,800 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.09 (OQB). Source: Nexqual, September 8, 2026 at 14:08 UTC.

Key Statistics (as of September 8, 2026 at 14:08 UTC)

Technical Analysis (BIXT)

Nexqual's technical model rates BIXT "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 14:08 UTC.

From Bioxytran, Inc's Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• During viral infections galectins are upregulated and downregulated based on the type of virus.   To our knowledge, Pharmalectin, Inc. is the only company planning to develop a viable end-to-end solution for Covid-19.
• We will rely on a combination of patent applications, patent, trade secrets, proprietary know-how and trademarks to protect our proprietary rights.
• To produce BXT-25, we will take red blood cells (RBCs) from camel sources, isolate hemoglobin from the RBCs and, by applying our proprietary co-polymer chemistry, stabilize and modify the hemoglobin.
• Our technology involves the development of hemoglobin-based oxygen carriers.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:08 UTC. This page is informational and not investment advice.